SARS CoV-2
14
4
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
7%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Dapagliflozin for Long COVID Syndrome
MxA-Guided Antiviral Treatment in Respiratory Viral Infections
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy
mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes
Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)
Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients
AnaConDa-therapy in COVID-19 Patients
Capturing Infectious COVID-19 Asymptomatic Cases in Singapore
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests